Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
Articolo
Data di Pubblicazione:
2017
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Abdominal Wall; Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Back; Chemotherapy; Adjuvant; Child; Dacarbazine; Deoxycytidine; Dioxoles; Disease-Free Survival; Epirubicin; Etoposide; Extremities; Humans; Ifosfamide; Leiomyosarcoma; Liposarcoma; Myxoid; Middle Aged; Neoadjuvant Therapy; Neurilemmoma; Neutropenia; Risk Factors; Sarcoma; Sarcoma; Synovial; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; Thoracic Wall; Thrombocytopenia; Young Adult; Oncology
Elenco autori:
Gronchi, A; Ferrari, S; Quagliuolo, V; Martin Broto, J; Lopez Pousa, A; Grignani, G; Basso, U; Blay, Jy; Tendero, O; Diaz Beveridge, R; Ferraresi, V; Lugowska, I; Merlo, Df; Fontana, V; Marchesi, E; Donati, Dm; Palassini, E; Palmerini, E; De Sanctis, R; Morosi, C; Stacchiotti, S; Bagué, S; Coindre, Jm; Dei Tos, Ap; Picci, P; Bruzzi, P; Casali, Pg
Link alla scheda completa:
Pubblicato in: